# Efficacy of Oral Citicoline in Neuro-Inflammation

## How effective is oral citicoline for neuro-inflammation?

Studies indicate oral citicoline (500-2000mg/day) improves recovery outcomes in neuro-inflammatory conditions with minimal side effects, particularly at higher doses.

## Abstract

This report examined three studies investigating oral citicoline for neuro-inflammation: two meta-analyses of stroke treatments and one pilot study of non-arteritic ischemic optic neuropathy (NAION).

The included stroke meta-analyses reported that citicoline treatment within 24 hours of onset was associated with higher rates of complete recovery at 3 months compared to controls (25.2% vs 20.2%, OR 1.33, 95% CI 1.10-1.62). In the NAION pilot study, patients showed improvements in visual function parameters after 6 months of treatment, with effects continuing through a 3-month wash-out period.

Across the studies, dosages ranged from 500 to 2000 mg/day, with the stroke meta-analyses reporting greater effects at higher doses. Treatment periods varied from 6 weeks to 6 months. The included studies reported minimal adverse events with citicoline administration.

Several limitations affect interpretation of these findings: only three studies were included, they covered different neurological conditions, and full-text access was unavailable for two meta-analyses. Additional research appears needed to determine optimal dosing, treatment duration, and effectiveness across various neuro-inflammatory conditions.

## Methods

We analyzed 3 sources from an initial pool of 96, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

### Papers identified with Elicit search

- n = 96

Papers screened using: Population Type, Administration Route, Outcome Measures, Study Design, Intervention Isolation, Study Model, Administration Method

- n = 96

Papers screened out

- n = 93

Papers included for extraction

- n = 3

## Data extraction

### Study Design:

- Identify and record the specific type of study design.

### Randomization Process:

- Examine the methods section for details about randomization.

### Participant Characteristics:

- Total number of participants
- Medical condition/diagnosis
- Age range or mean age
- Gender distribution
- Inclusion and exclusion criteria

### Citicoline Intervention:

- Dosage (mg/day)
- Route of administration 
- Duration of intervention 
- Frequency of administration

### Primary Outcome Measures:

- Specific measurement tools used 
- Time points of outcome assessment 
- Key results for each primary outcome

### Safety and Adverse Events:

- Reported adverse events
- Mortality rates
- Any significant safety findings

## Results

### Characteristics of Included Studies

| Study                             | Full text retrieved | Study Design                                        | Population Size                                  | Treatment Protocol                                | Primary Outcomes                                      |
|-----------------------------------|---------------------|-----------------------------------------------------|--------------------------------------------------|-----------------------------------------------------|------------------------------------------------------|
| Dávalos et al., 2002              | No                  | Meta-analysis of prospective, randomized, placebo-controlled, double-blind clinical trials | 1372 patients with acute ischemic stroke         | Oral citicoline (500, 1000, or 2000 mg/day) for at least 6 weeks | Combined eval using NIH Stroke Scale, modified Rankin Scale |
| EFSA NDA Panel, 2018             | No                  | Meta-analysis of placebo-controlled, double-blind, randomized clinical trials             | 1372 subjects (789 citicoline, 583 placebo)    | Oral citicoline (500, 1000, or 2000 mg/day) for at least 6 weeks | Efficacy endpoints using Barthel index, NIHSS       |
| Parisi et al., 2019              | Yes                 | Randomized, monocentric, prospective, operator-masked pilot study                         | 36 patients with NAION and 20 age-matched controls | 500 mg/day of oral citicoline solution for 6 months, followed by 3-month wash-out | Visual Acuity, Pattern Electroretinogram, Visual Evoked Potentials  |

### Effects

#### Clinical Effectiveness

| Study                             | Dosage Level                      | Treatment Duration | Efficacy Measures                                   | Safety Profile                                    |
|-----------------------------------|-----------------------------------|--------------------|-----------------------------------------------------|---------------------------------------------------|
| Dávalos et al., 2002              | 500, 1000, 2000 mg/day            | At least 6 weeks   | 25.2% recovery in citicoline-treated patients vs 20.2% in placebo (OR 1.33, 95% CI 1.10-1.62) | Overall safety similar to placebo                 |
| EFSA NDA Panel, 2018             | 500, 1000, 2000 mg/day            | At least 6 weeks   | Not specified in abstract                            | No significant differences in mortality            |
| Parisi et al., 2019              | 500 mg/day                        | 6 months           | Significant improvements in Visual Acuity, Pattern Electroretinogram, etc. (p<0.01)        | No adverse side effects reported                   |

### Treatment Timing and Duration

| Study                             | Administration Timing | Duration of Treatment | Follow-up Period | Observed Effects                               |
|-----------------------------------|----------------------|-----------------------|------------------|-----------------------------------------------|
| Dávalos et al., 2002              | Within 24 hours of stroke onset | At least 6 weeks      | 3 months         | Increased probability of complete recovery    |
| EFSA NDA Panel, 2018             | Not specified         | At least 6 weeks      | 3 months         | Not specified in abstract                     |
| Parisi et al., 2019              | Not specified for NAION onset   | 6 months              | 9 months        | Significant improvements in visual function    |

## References

1. [Parisi et al., 2019](/content/review/b67b512d-efa4-42b8-a7ba-35e67fe8e8cd/source/323d608a84c84bed9ed60da187e077cd/index.html) - Neuroenhancement and neuroprotection by oral solution citicoline.
2. [Dávalos et al., 2002](/content/review/b67b512d-efa4-42b8-a7ba-35e67fe8e8cd/source/2a4fc71c15ce4fdba438034578bc3abb/index.html) - Oral Citicoline in Acute Ischemic Stroke.
3. [EFSA NDA Panel, 2018](/content/review/b67b512d-efa4-42b8-a7ba-35e67fe8e8cd/source/957d1a175d84420388f91f1454a58d2c/index.html) - Scientific on the safety of citicoline.